BACKGROUND: Solitomab is a novel, bispecific, single-chain antibody that targets epithelial cell adhesion molecule (EpCAM) on tumor cells and also contains a cluster of differentiation 3 (CD3) (T-cell coreceptor) binding region. The authors evaluated the in vitro activity of solitomab against primary chemotherapy-resistant epithelial ovarian carcinoma cell lines as well as malignant cells in ascites. METHODS: EpCAM expression was evaluated by flow cytometry in 5 primary ovarian cancer cell lines and in 42 fresh ovarian tumor cell cultures in ascites from patients with mainly advanced or recurrent, chemotherapy-resistant disease. The potential activity of solitomab against EpCAM-positive tumor cells was evaluated by flow cytometry, proliferation, and 4-hour chromium-release, cell-mediated cytotoxicity assays. RESULTS: EpCAM expression was detected by flow cytometry in approximately 80% of the fresh ovarian tumors and primary ovarian tumor cell lines tested. EpCAM-positive, chemotherapy-resistant cell lines were identified as resistant to natural killer cell-mediated or T-cell-mediated killing after exposure to peripheral blood lymphocytes in 4-hour chromium-release assays (mean±standard error of the mean, 3.6%±0.7% of cells killed after incubation of EpCAM-positive cell lines with control bispecific antibody). In contrast, after incubation with solitomab, EpCAM-positive, chemotherapy-resistant cells became highly sensitive to T-cell cytotoxicity (mean±standard error of the mean, 28.2%±2.05% of cells killed; P<.0001) after exposure to peripheral blood lymphocytes. Ex vivo incubation of autologous tumor-associated lymphocytes with EpCAM-expressing malignant cells in ascites with solitomab resulted in a significant increase in T-cell activation markers and a reduction in the number of viable ovarian tumor cells in ascites (P<.001). CONCLUSIONS: Solitomab may represent a novel, potentially effective agent for the treatment of chemotherapy-resistant ovarian cancers that overexpress EpCAM.
BACKGROUND:Solitomab is a novel, bispecific, single-chain antibody that targets epithelial cell adhesion molecule (EpCAM) on tumor cells and also contains a cluster of differentiation 3 (CD3) (T-cell coreceptor) binding region. The authors evaluated the in vitro activity of solitomab against primary chemotherapy-resistant epithelial ovarian carcinoma cell lines as well as malignant cells in ascites. METHODS:EpCAM expression was evaluated by flow cytometry in 5 primary ovarian cancer cell lines and in 42 fresh ovarian tumor cell cultures in ascites from patients with mainly advanced or recurrent, chemotherapy-resistant disease. The potential activity of solitomab against EpCAM-positive tumor cells was evaluated by flow cytometry, proliferation, and 4-hour chromium-release, cell-mediated cytotoxicity assays. RESULTS:EpCAM expression was detected by flow cytometry in approximately 80% of the fresh ovarian tumors and primary ovarian tumor cell lines tested. EpCAM-positive, chemotherapy-resistant cell lines were identified as resistant to natural killer cell-mediated or T-cell-mediated killing after exposure to peripheral blood lymphocytes in 4-hour chromium-release assays (mean±standard error of the mean, 3.6%±0.7% of cells killed after incubation of EpCAM-positive cell lines with control bispecific antibody). In contrast, after incubation with solitomab, EpCAM-positive, chemotherapy-resistant cells became highly sensitive to T-cell cytotoxicity (mean±standard error of the mean, 28.2%±2.05% of cells killed; P<.0001) after exposure to peripheral blood lymphocytes. Ex vivo incubation of autologous tumor-associated lymphocytes with EpCAM-expressing malignant cells in ascites with solitomab resulted in a significant increase in T-cell activation markers and a reduction in the number of viable ovarian tumor cells in ascites (P<.001). CONCLUSIONS:Solitomab may represent a novel, potentially effective agent for the treatment of chemotherapy-resistant ovarian cancers that overexpress EpCAM.
Authors: Klaus Brischwein; Bernd Schlereth; Benjamin Guller; Carola Steiger; Andreas Wolf; Ralf Lutterbuese; Sonja Offner; Mathias Locher; Thomas Urbig; Tobias Raum; Petra Kleindienst; Pauline Wimberger; Rainer Kimmig; Iduna Fichtner; Peter Kufer; Robert Hofmeister; Antonio J da Silva; Patrick A Baeuerle Journal: Mol Immunol Date: 2005-09-01 Impact factor: 4.407
Authors: Bernd Schlereth; Iduna Fichtner; Grit Lorenczewski; Petra Kleindienst; Klaus Brischwein; Antonio da Silva; Peter Kufer; Ralf Lutterbuese; Ilse Junghahn; Sabine Kasimir-Bauer; Pauline Wimberger; Rainer Kimmig; Patrick A Baeuerle Journal: Cancer Res Date: 2005-04-01 Impact factor: 12.701
Authors: Robert E Bristow; Rafael S Tomacruz; Deborah K Armstrong; Edward L Trimble; F J Montz Journal: J Clin Oncol Date: 2002-03-01 Impact factor: 44.544
Authors: S V Litvinov; M Balzar; M J Winter; H A Bakker; I H Briaire-de Bruijn; F Prins; G J Fleuren; S O Warnaar Journal: J Cell Biol Date: 1997-12-01 Impact factor: 10.539
Authors: S Bellone; R Tassi; M Betti; D English; E Cocco; S Gasparrini; I Bortolomai; J D Black; P Todeschini; C Romani; A Ravaggi; E Bignotti; E Bandiera; L Zanotti; S Pecorelli; L Ardighieri; M Falchetti; C Donzelli; E R Siegel; M Azodi; D-A Silasi; E Ratner; P E Schwartz; T J Rutherford; A D Santin Journal: Br J Cancer Date: 2013-06-27 Impact factor: 7.640
Authors: Stefania Bellone; Jonathan Black; Diana P English; Carlton L Schwab; Salvatore Lopez; Emiliano Cocco; Elena Bonazzoli; Federica Predolini; Francesca Ferrari; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Alessandro D Santin Journal: Am J Obstet Gynecol Date: 2015-08-10 Impact factor: 8.661
Authors: Francesca Ferrari; Stefania Bellone; Jonathan Black; Carlton L Schwab; Salvatore Lopez; Emiliano Cocco; Elena Bonazzoli; Federica Predolini; Gulden Menderes; Babak Litkouhi; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Alessandro D Santin Journal: J Exp Clin Cancer Res Date: 2015-10-17
Authors: Satyen Harish Gohil; Solange Rosa Paredes-Moscosso; Micaela Harrasser; Marzia Vezzalini; Aldo Scarpa; Emma Morris; Andrew M Davidoff; Claudio Sorio; Amit Chunilal Nathwani; Marco Della Peruta Journal: Oncoimmunology Date: 2017-05-17 Impact factor: 8.110